Is peptide receptor radionuclide therapy an option after liver transplantation in progressive metastatic neuroendocrine tumors?

被引：0
|
作者：
Kulkarni, Harshad [1 ]
Kaemmerer, Daniel [2 ]
Hoersch, Dieter [3 ]
Hommann, Merten [2 ]
Baum, Richard [1 ]
机构：
[1] Zent Klin, Mol Radiotherapy & Mol Imaging, Bad Berka, Germany
[2] Zent Klin, Gen & Visceral Surg, Bad Berka, Germany
[3] Zent Klin, Internal Med Gastroenterol & Endocrinol, Bad Berka, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1177
引用
收藏
页数：2
相关论文
共 50 条
  • [31] AN ALTERNATIVE THERAPY OPTION IN METASTATIC THYROID CANCER: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY
    Cinkir, Havva Yesil
    Elboga, Umut
    JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, 2020, 83 (04): : 339 - 344
  • [32] Peptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated β-Emitter Peptide Receptor Radionuclide Therapy
    Zhang, Jingjing
    Kulkarni, Harshad R.
    Baum, Richard P.
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (03) : 241 - 243
  • [33] Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors
    Alayli, Adam
    Ngo, Hoang
    Sikaria, Dhiraj
    Ahmed, Altan
    Salloum, Elias
    Strosberg, Jonathan R.
    Al-Toubah, Taymeyah E.
    Kis, Bela
    Haider, Mintallah
    El-Haddad, Ghassan
    CANCERS, 2024, 16 (15)
  • [34] The use of peptide receptor radionuclide therapy in patients with metastatic low-grade neuroendocrine tumors.
    Naraev, Boris
    Sharma, Nancy
    Engelman, Eric Steven
    Bushnell, David L.
    O'Dorisio, Thomas M.
    Halfdanarson, Thorvardur Ragnar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [35] Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Metastatic Low Grade Neuroendocrine Tumors (mNETs)
    Naraev, Boris G.
    Sharma, Nancy
    Engelman, Eric S.
    Bushnell, David L., Jr.
    O'Dorisio, Thomas M.
    Halfdanarson, Thorvardur R.
    PANCREAS, 2012, 41 (02) : 347 - 348
  • [36] Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs)
    Baum, Richard P.
    Wang, Peipei
    Jakobsson, Vivianne
    Zhao, Tianzhi
    Schuchardt, Christiane
    Khong, Pek-Lan
    Zhang, Jingjing
    THERANOSTICS, 2024, 14 (01): : 133 - 142
  • [37] Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs) in a United States (US) Population
    Katona, Bryson W.
    Riff, Brian P.
    Soulen, Michael C.
    Pryma, Daniel A.
    Bennett, Bonita J.
    Wild, Damian
    Nicolas, Guillaume
    Teitelbaum, Ursina R.
    Metz, David C.
    GASTROENTEROLOGY, 2016, 150 (04) : S208 - S209
  • [38] Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience
    Kesavan, Murali
    Turner, J. Harvey
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2016, 31 (06) : 189 - 198
  • [39] Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives
    Santo, Giulia
    Di Santo, Gianpaolo
    Virgolini, Irene
    SEMINARS IN NUCLEAR MEDICINE, 2024, 54 (04) : 557 - 569
  • [40] MYELOTOXICITY OF PEPTIDE RECEPTOR RADIONUCLIDE THERAPY OF NEUROENDOCRINE TUMORS: A DECADE OF EXPERIENCE
    Kesavan, M.
    Turner, J. H.
    HAEMATOLOGICA, 2016, 101 : 776 - 777
12345